Clinical Trial Update: Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults [Phase 2]

View source ↗

Summary

Phase 2 trial comparing E/C/F/TAF (Genvoya) to E/C/F/TDF (Stribild) in ART-naive adults with HIV-1, assessing safety and efficacy; completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• HIV Infections

Drugs mentioned

• Genvoya (elvitegravir; cobicistat; emtricitabine; tenofovir alafenamide)
• Stribild (elvitegravir; cobicistat; emtricitabine; tenofovir disoproxil fumarate)

Snippet

Sponsor: Gilead Sciences | Conditions: Acquired Immunodeficiency Syndrome, HIV Infections | Phase 2 | Status: COMPLETED | Results posted: 2016-01-08